<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00135837</url>
  </required_header>
  <id_info>
    <org_study_id>CBPD952B2401</org_study_id>
    <nct_id>NCT00135837</nct_id>
  </id_info>
  <brief_title>Photodynamic Therapy in Occult-Only Lesions (POOL)</brief_title>
  <official_title>An Open-Label, Multicenter, Phase 4 Study of the Effect of Verteporfin for Injection Therapy in Subjects With Occult With No Classic Choroidal NeoVascularization Secondary to Age-Related Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>QLT Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      Age related macular degeneration is the leading cause of blindness for people over 50 in the
      western world. Blood vessels which start to grow form a lesion in the back of the eye.
      Verteporfin may stabilize the disease, by closing the blood vessels. This study will assess
      the efficacy and safety of verteporfin in patients with occult only lesions.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2003</start_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>visual acuity measurements, baseline, 12 months</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>visual acuity measurements, fundus photographs and fluorescein angiography at baseline, 12 months; ophthalmic examinations, adverse events, vital signs, concomitant medications, 12 months</measure>
  </secondary_outcome>
  <enrollment>202</enrollment>
  <condition>Age-Related Macular Degeneration</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Verteporfin for injection</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  50 years or older

          -  Must see better or equal to 34 letters (visual acuity)

          -  Choroidal neovascularization (CNV) lesion must be occult only

        Exclusion Criteria:

          -  Evidence of classic CNV in the lesion

          -  Prior treatment of disease in study eye

          -  Have a history of moderate to severe hepatic impairment

        Other protocol-defined exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Customer Information</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis</name>
      <address>
        <city>Basel</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>June 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 24, 2005</study_first_submitted>
  <study_first_submitted_qc>August 24, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2005</study_first_posted>
  <last_update_submitted>June 20, 2006</last_update_submitted>
  <last_update_submitted_qc>June 20, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 21, 2006</last_update_posted>
  <keyword>Age related Macula Degeneration,</keyword>
  <keyword>AMD,</keyword>
  <keyword>choroidal neovascularisation (CNV),</keyword>
  <keyword>occult CNV lesion,</keyword>
  <keyword>verteporfin for injection,</keyword>
  <keyword>photodynamic therapy (PDT)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Choroidal Neovascularization</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Verteporfin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

